JP2012500260A - Ｍｉｆモジュレーター - Google Patents

Ｍｉｆモジュレーター Download PDF

Info

Publication number
JP2012500260A
JP2012500260A JP2011523805A JP2011523805A JP2012500260A JP 2012500260 A JP2012500260 A JP 2012500260A JP 2011523805 A JP2011523805 A JP 2011523805A JP 2011523805 A JP2011523805 A JP 2011523805A JP 2012500260 A JP2012500260 A JP 2012500260A
Authority
JP
Japan
Prior art keywords
optionally substituted
group
alkyl
mif
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500260A5 (enExample
Inventor
ウィリアム・ヨルゲンセン
リチャード・ジェイ・ブカラ
Original Assignee
イェール・ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012500260(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イェール・ユニヴァーシティー filed Critical イェール・ユニヴァーシティー
Publication of JP2012500260A publication Critical patent/JP2012500260A/ja
Publication of JP2012500260A5 publication Critical patent/JP2012500260A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
JP2011523805A 2008-08-18 2009-08-18 Ｍｉｆモジュレーター Pending JP2012500260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18932708P 2008-08-18 2008-08-18
US61/189,327 2008-08-18
PCT/US2009/004704 WO2010021693A2 (en) 2008-08-18 2009-08-18 Mif modulators

Publications (2)

Publication Number Publication Date
JP2012500260A true JP2012500260A (ja) 2012-01-05
JP2012500260A5 JP2012500260A5 (enExample) 2012-10-04

Family

ID=41707595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523805A Pending JP2012500260A (ja) 2008-08-18 2009-08-18 Ｍｉｆモジュレーター

Country Status (14)

Country Link
US (1) US20120040974A1 (enExample)
EP (1) EP2326631A4 (enExample)
JP (1) JP2012500260A (enExample)
KR (1) KR20110042374A (enExample)
CN (1) CN102186833A (enExample)
AU (1) AU2009283195A1 (enExample)
BR (1) BRPI0917394A2 (enExample)
CA (1) CA2733554A1 (enExample)
CL (1) CL2011000352A1 (enExample)
EA (1) EA201170349A1 (enExample)
IL (1) IL211170A0 (enExample)
MX (1) MX2011001872A (enExample)
PE (1) PE20110368A1 (enExample)
WO (1) WO2010021693A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515526A (ja) * 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
JP2016525078A (ja) * 2013-06-21 2016-08-22 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10363257B2 (en) 2013-06-21 2019-07-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044622A1 (en) 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
DK2308877T3 (da) 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
TW201107315A (en) 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
US20110257233A1 (en) * 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
CN103172578B (zh) * 2011-12-20 2016-09-14 天津市国际生物医药联合研究院 4-环末端取代2-1,2,3-三氮唑苯胺类化合物的制备和用途
CN103172579B (zh) * 2011-12-20 2017-02-22 天津市国际生物医药联合研究院 三氮唑苯胺类化合物的制备和用途
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9382245B2 (en) 2013-10-11 2016-07-05 Yale University Compounds and methods for treating HIV infections
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
ES2683716T3 (es) * 2014-04-10 2018-09-27 Mifcare Inhibidores de MIF
EP2944310B1 (en) 2014-05-16 2018-03-21 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
BR112017006708A2 (pt) * 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180109A (es) 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3519416T1 (sl) 2016-09-27 2021-08-31 Merck Sharp & Dohme Corp. Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN107188864B (zh) * 2017-07-28 2019-06-04 安徽师范大学 一种n-苄基苯并噁唑酮类化合物及其合成方法
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
CA3161323A1 (en) 2019-12-10 2021-06-17 Shanghai Zhimeng Biopharma, Inc. Compound having neuroprotective effect, preparation method therefor and use thereof
US20230404980A1 (en) * 2020-10-28 2023-12-21 University Health Network Methods of treating spondyloarthritis or symptoms thereof
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CN114028399A (zh) * 2021-12-18 2022-02-11 郑琳 一种mif抑制剂4-ipp在制备治疗脑胶质瘤药物的应用
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途
CN118490617B (zh) * 2024-05-14 2024-12-13 中山大学孙逸仙纪念医院 一种治疗皮肤型红斑狼疮的经皮微针贴片及其制备方法和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262278A (en) * 1975-11-13 1977-05-23 Hoechst Ag Production of novel imidazole compound and pharmaceutical agent
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JPH10259182A (ja) * 1997-01-14 1998-09-29 Snow Brand Milk Prod Co Ltd 新規ベンゾフラノン誘導体及びその製造方法
JP2004511440A (ja) * 2000-08-14 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
WO2004037829A1 (fr) * 2002-10-18 2004-05-06 Les Laboratoires Servier Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2005533049A (ja) * 2002-06-07 2005-11-04 コーティカル・ピーティーワイ・リミテッド 治療用分子および方法−１
WO2006129164A1 (en) * 2005-05-31 2006-12-07 Pfizer Japan Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007070961A1 (en) * 2005-12-21 2007-06-28 Cortical Pty Ltd Mif inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517587A1 (ru) * 1971-08-23 1976-06-15 Медицинска Академие (Инопредприятие) Способ получени производных 2оксфенилмочевины
FR2244506B1 (enExample) * 1973-06-26 1977-02-25 Inst Nat Sante Rech Med
DD111637A1 (enExample) * 1974-05-13 1975-03-05
EP0200345A3 (en) * 1985-03-30 1988-03-02 Beecham Group Plc Anti-allergic or anti-inflammatory substituted (hetero)-aralkylamino-ortho-phenols
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
EP0944388A4 (en) * 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ZA974030B (en) * 1996-05-15 1998-02-19 Bayer Ag Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
ATE305466T1 (de) * 2000-06-05 2005-10-15 Austria Wirtschaftsserv Gmbh Heterocyclische hydrazone als anti-krebs- wirkstoffe
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
YU52403A (sh) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
US6515176B1 (en) * 2001-12-03 2003-02-04 Eastman Kodak Company 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR041198A1 (es) * 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
GB0423405D0 (en) * 2004-10-21 2004-11-24 Novartis Ag Organic compounds
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
US7576099B2 (en) * 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
NZ570835A (en) * 2006-03-08 2011-11-25 Achillion Pharmaceuticals Inc Substituted aminothiazole derivatives with anti-HCV activity
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
DE102007026341A1 (de) * 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
TWI428091B (zh) * 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
EP2402332A3 (en) * 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US8497381B2 (en) * 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262278A (en) * 1975-11-13 1977-05-23 Hoechst Ag Production of novel imidazole compound and pharmaceutical agent
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JPH10259182A (ja) * 1997-01-14 1998-09-29 Snow Brand Milk Prod Co Ltd 新規ベンゾフラノン誘導体及びその製造方法
JP2004511440A (ja) * 2000-08-14 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
JP2005533049A (ja) * 2002-06-07 2005-11-04 コーティカル・ピーティーワイ・リミテッド 治療用分子および方法−１
WO2004037829A1 (fr) * 2002-10-18 2004-05-06 Les Laboratoires Servier Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
WO2006129164A1 (en) * 2005-05-31 2006-12-07 Pfizer Japan Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007070961A1 (en) * 2005-12-21 2007-06-28 Cortical Pty Ltd Mif inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 18, JPN6014005093, 1998, pages 2467 - 2472, ISSN: 0002741505 *
DATABASE REGISTRY, JPN7014000455, ISSN: 0002741500 *
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. Vol.21, No.2-3, JPN6014005090, 2004, pages 115 - 118, ISSN: 0002741502 *
FARMACO, EDIZIONE SCIENTIFICA, vol. 19, no. 2, JPN6014005088, 1964, pages 121 - 136, ISSN: 0002741499 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 5, JPN6014005092, March 2008 (2008-03-01), pages 1482 - 1486, ISSN: 0002741504 *
KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 16, no. 3, JPN6014005091, 1982, pages 291 - 294, ISSN: 0002741503 *
MOLECULES, vol. 10, no. 11, JPN6014005089, 2005, pages 1399 - 1408, ISSN: 0002741501 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515526A (ja) * 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
JP2016525078A (ja) * 2013-06-21 2016-08-22 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
US10166215B2 (en) 2013-06-21 2019-01-01 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10226451B2 (en) 2013-06-21 2019-03-12 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10363257B2 (en) 2013-06-21 2019-07-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10772892B2 (en) 2013-06-21 2020-09-15 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US11026926B2 (en) 2013-06-21 2021-06-08 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US11446306B2 (en) 2013-06-21 2022-09-20 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains

Also Published As

Publication number Publication date
CA2733554A1 (en) 2010-02-25
EP2326631A4 (en) 2012-03-21
PE20110368A1 (es) 2011-06-13
IL211170A0 (en) 2011-04-28
EP2326631A2 (en) 2011-06-01
MX2011001872A (es) 2011-05-23
WO2010021693A2 (en) 2010-02-25
EA201170349A1 (ru) 2011-08-30
CL2011000352A1 (es) 2011-09-23
AU2009283195A1 (en) 2010-02-25
WO2010021693A3 (en) 2010-07-01
US20120040974A1 (en) 2012-02-16
KR20110042374A (ko) 2011-04-26
CN102186833A (zh) 2011-09-14
BRPI0917394A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
US11584717B2 (en) MIF modulators
US9643922B2 (en) MIF modulators
US20120040974A1 (en) Mif modulators
CN103889953B (zh) 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
KR102034618B1 (ko) Dna 알킬화제
CN104918612B (zh) 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
CN103450077B (zh) IRE-1α抑制剂
MXPA02001565A (es) Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP2964617B1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP2011524383A (ja) ６−１ｈ−イミダゾ−キナゾリンおよびキノリン誘導体、新規ｍａｏ阻害剤およびイミダゾリンレセプターリガンド
KR20180071412A (ko) 지질 합성의 헤테로사이클릭 조절자
CN101528728B (zh) 6-1h-咪唑并-喹唑啉和喹啉衍生物，镇痛剂和抗炎剂
US10428041B2 (en) Pyridyl reverse sulfonamides for HBV treatment
KR20220085774A (ko) 벤즈이미다졸 및 이의 사용 방법
AU2004212957A1 (en) Novel compounds
EP3107911B1 (en) Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
ES2308916B1 (es) Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
WO2013075596A1 (zh) 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用
CA3233233A1 (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
CA2482022A1 (en) Novel compounds
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
US20110306621A1 (en) Acylguanidine derivatives
KR20080035571A (ko) 신규 약학적 화합물들
JP6052673B2 (ja) ピラゾール誘導体またはその塩ならびにそれらを含有する医薬組成物
CN114315827A (zh) 多环吡啶并哒嗪酰胺并含肟碳环衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140707